<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00344526</url>
  </required_header>
  <id_info>
    <org_study_id>I00001</org_study_id>
    <nct_id>NCT00344526</nct_id>
  </id_info>
  <brief_title>Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis</brief_title>
  <official_title>Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone in Patients With AL (Primary)Amyloidosis. A Prospective Randomized Trial .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <brief_summary>
    <textblock>
      AL amyloidosis is caused by a clonal plasma cell dyscrasia and characterized by progressive
      deposition of amyloid fibrils derived from monoclonal Ig light chains, leading to multisystem
      organ failure and death. The prognosis for AL amyloidosis with conventional treatment remains
      poor, Autologous stem cell transplantation (ASCT) for AL amyloidosis produces high
      hematologic and organ responses. However, treatment-related mortality remains high and
      reported series are subject to selection bias.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized trial was conducted to compare in AL amyloidosis ASCT (melphalan 140
      or 200 mg/m2 depending on age and clinical status supported with ASCT collected with G-CSF
      alone) and the oral regimen M-Dex (melphalan 10 mg/m2 and dexamethasone 40 mg for 4 days each
      months up to 18 months). The objectives were to compare survival and hematologic and clinical
      responses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>hematologic responses</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical responses</measure>
  </secondary_outcome>
  <enrollment>100</enrollment>
  <condition>Primary Systemic Amyloidosis (AL)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  below 70 years of age

          -  biopsy proven systemic AL amyloidosis

          -  no more than 2 prior courses of chemotherapy

          -  ECOG performance status &lt; 3

          -  Informed written consent

        Exclusion Criteria:

          -  localized amyloidosis

          -  HIV seropositivity

          -  previous myelodysplasia

          -  concomitant serious disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud Jaccard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Limoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service des Maladies du Sang</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie et de Thérapie cellulaire</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'hématologie clinique</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'hématologie clinique, Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'immuno-hématologie, Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d’hématologie Clinique, Groupe Hospitalier Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'hématologie</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hématologie Clinique</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2006</study_first_submitted>
  <study_first_submitted_qc>June 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2006</study_first_posted>
  <last_update_submitted>June 27, 2007</last_update_submitted>
  <last_update_submitted_qc>June 27, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2007</last_update_posted>
  <keyword>AL amyloidosis</keyword>
  <keyword>Autologous stem cell transplantation</keyword>
  <keyword>Melphalan</keyword>
  <keyword>Dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

